{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:23:26Z","timestamp":1794569006106,"version":"4.9.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"name":"GSK","award":["BEL114054"],"award-info":[{"award-number":["BEL114054"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. This 28-week open-label extension of BLISS-LN assessed belimumab\u2019s safety and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      Eligible patients completing BLISS-LN received monthly intravenous belimumab 10 mg\/kg plus standard therapy. End points included safety, open-label week 28 primary efficacy renal response (urine protein-creatinine ratio [UPCR] \u22640.7, eGFR no more than 20% below open-label baseline value or \u226560 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , no prohibited medications) and complete renal response (UPCR &lt;0.5, eGFR\u2009no more than 10% below open-label baseline value or \u226590 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , no prohibited medications), and UPCR and eGFR by visit. Responses were also analyzed\n                      <jats:italic toggle=\"yes\">post hoc<\/jats:italic>\n                      using the double-blind phase criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 257 enrolled patients, 255 were treated (safety population:\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =123 switched from placebo-to-belimumab;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =132 remained on belimumab); 245 (97%) patients completed the study. Adverse events and serious adverse events were experienced by 62% and 4% of placebo-to-belimumab patients, respectively, and by 70% and 8% of belimumab-to-belimumab patients, respectively. One death occurred in the placebo-to-belimumab group. From open-label baseline to week 28, increases occurred in the proportions of patients achieving primary efficacy renal response (placebo-to-belimumab: from 60% to 67%; belimumab-to-belimumab: from 70% to 75%) and complete renal response (placebo-to-belimumab: from 36% to 48%; belimumab-to-belimumab: from 48% to 62%). Based on double-blind phase criteria, changes also occurred in the proportions achieving primary efficacy renal response (placebo-to-belimumab: from 54% to 53%; belimumab-to-belimumab: from 66% to 52%) and complete renal response (placebo-to-belimumab: from 34% to 35%; belimumab-to-belimumab: from 46% to 41%). The seeming decrease in response rates in the belimumab-to-belimumab groups was attributed to discontinuations\/administration of glucocorticoids for non-SLE reasons as opposed to nephritis. Median UPCR and eGFR values were similar at open-label baseline and week 28.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No new safety signals were identified, and efficacy was generally maintained throughout the open-label phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial registry name and registration number:<\/jats:title>\n                    <jats:p>BLISS-LN, NCT01639339<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.02520322","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T11:05:31Z","timestamp":1666868731000},"page":"1620-1630","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":83,"title":["Safety and Efficacy of Belimumab in Patients with Lupus Nephritis"],"prefix":"10.2215","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct01639339","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-1585","authenticated-orcid":false,"given":"Richard","family":"Furie","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Great Neck, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Houssiau","sequence":"additional","affiliation":[{"name":"P\u00f4le de Pathologies Rhumatismales Inflammatoires et Syst\u00e9miques, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain and Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Contreras","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Division of Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Y.K. Onno","family":"Teng","sequence":"additional","affiliation":[{"name":"Expert Center for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases, Department of Internal Medicine, Section of Nephrology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-5468","authenticated-orcid":false,"given":"Paula","family":"Curtis","sequence":"additional","affiliation":[{"name":"GSK, Brentford, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Green","sequence":"additional","affiliation":[{"name":"GSK, Brentford, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5610-8083","authenticated-orcid":false,"given":"Mohamed","family":"Okily","sequence":"additional","affiliation":[{"name":"GSK, Brentford, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-5422","authenticated-orcid":false,"given":"Anuradha","family":"Madan","sequence":"additional","affiliation":[{"name":"GSK, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8356-0457","authenticated-orcid":false,"given":"David A.","family":"Roth","sequence":"additional","affiliation":[{"name":"GSK, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: Results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0961203320932219","article-title":"Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression","volume":"29","author":"Mahajan","year":"2020","journal-title":"Lupus"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: A systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.ki.5002118","article-title":"The ISN\/RPS 2003 classification of lupus nephritis: An assessment at 3 years","volume":"71","author":"Markowitz","year":"2007","journal-title":"Kidney Int"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203318777634","article-title":"A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus","volume":"27","author":"Doria","year":"2018","journal-title":"Lupus"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/kez279","article-title":"Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: A phase III study extension","volume":"59","author":"van Vollenhoven","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"B16-20241015","doi-asserted-by":"crossref","first-page":"gfab121.003","DOI":"10.1093\/ndt\/gfab121.003","article-title":"Safety and efficacy of intravenous belimumab in patients with lupus nephritis: A 6-month open-label extension","volume":"36","author":"Rovin","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"B17-20241015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/annrheumdis-2021-eular.1583","article-title":"A 6-month open-label extension study of the safety and efficacy of intravenous belimumab in patients with lupus nephritis","volume":"80","author":"Furie","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.02520322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:47Z","timestamp":1786369487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.02520322"}},"subtitle":["Open-Label Extension of BLISS-LN Study"],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02520322","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"2022-03-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}